Dermatological Drugs Market Forecast 2018-2028 - Visiongain Report

Thursday, August 16, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, August 16, 2018 /PRNewswire/ --

Psoriasis, Skin Infection, Acne, Dermatitis, Others


revenue of the dermatological drugs market in 2017 is estimated at $26.07bn and is expected to grow at a CAGR of 5.8% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share
of the market in 2017, this segment accounted for 36% of the global dermatological drugs market.

     (Logo: )

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 333-page report you will receive 124 tables and 147 figures- all unavailable elsewhere.

The 333-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Dermatological drugs market forecasts from 2018-2028

• This report also breaks down the revenue forecast for the main submarkets: • Psoriasis • Skin Infections • Acne • Dermatitis

• Analysis of the Psoriasis drugs market. Revenue forecasts to 2028 are provided for the following drugs: • Humira • Stelara • Enbrel • Remicade • Taltz • Otezla • Cosentyx

• Analysis of the Skin Infections drugs market. Revenue forecasts to 2028 are provided for the following drugs: • Cubicin • Zyvox • Valtrex • Canesten • Lamisil • Bactroban

• Analysis of the Acne drugs market. Revenue forecasts to 2028 are provided for the following drugs: • Solodyn • Epiduo • Claravis • Aczone • Differin • Abscorical/Epirus • Ziana • Doryx

• Analysis of the Dermatitis drugs market. Revenue forecasts to 2028 are provided for the following drugs: • Bepanthen/Bepanthol • Protopic • Dermovate • Elocon

• This report provides individual revenue forecasts to 2028 for these regional and national markets: • North America: US & CanadaEurope: Germany, France, UK, Italy, Spain, Rest of EuropeAsia-Pacific: China, Japan, India, Rest of Asia-PacificLatin America: Brazil, Mexico, Rest of Latin AmericaMiddle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA

Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT analysis and Porter's Five Force analysis of the dermatological drugs market.

• Our study discusses the selected leading companies that are the major players in the dermatological drugs market: • AbbVie • Amgen • Bayer AG • Galderma (Nestle Skin Health S.A.) • GlaxoSmithKline (GSK) • Johnson & Johnson • LEO Pharma • Merck & Co, Inc. • Novartis • Pfizer

Our new report discusses issues and events affecting the dermatological drugs market: • Highly fragmented and competitive market with significant variations in different geographic regions • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities • Future paradigm-shifting pipeline products • Patent expirations • Launches of new drug categories • Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance

Visiongain's study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Buy our report today Dermatological Drugs Market Forecast 2018-2028: Psoriasis, Skin Infection, Acne, Dermatitis, Others.

To request a report overview of this report please contact Sara Peerun at or refer to our website :

Abbott AbbVie Actavis AET BioTech Alkem Laboratories Allergan Almirall Amgen Anacor Ascend Therapeutics Astellas Aurovindo Barr Labs Bayer Betta Pharmaceuticals Biocon/Mylan Biofrontera Biogen Biovail Laboratories BioXpress Therapeutics Boehringer Ingelheim Bristol-Myers Squibb Brazilian Society of Dermatology Cadila Healthcare Calico Can-Fite BioPharma Cassiopea SpA Celgene Celltrion Cempra Cipher Pharmaceuticals Cipla Colorescience Cubist Pharmaceuticals Cutanea Life Sciences Dow Pharmaceuticals Science Dr Reddy's Durata Therapeutics Eisai Eli Lilly European Medicines Agency (EMA) European Pharmaceutical Market Research Association (EPhMRA) FibroTx Food and Drug Association (FDA) Foamix Fougera Fujifilm Galapagos NV G&E Herbal Biotechnology Galderma GlaxoSmithKline Glenmark Pharmaceuticals Heritage Impax Incyte International Health Partners Janssen Biotech Johnson & Johnson Kyowa Hakko Kirin L'Oreal LEO Pharma Lupin Maruho Mayne Pharma Medicis Medison Pharma Melinta Pharmaceuticals Merck Merz Pharmaceuticals Mitsubishi Tanabe MorphoSys Mylan NanoBio Corporation National Psoriasis Foundation (NPF) NeoStrata Compnay Inc Nestle Skin Health Novan Novartis Perriogo Pfizer PharmaPraxis Photocure Pierre Fabre Provectus Biopharmaceuticals QLT Inc Ranbaxy Regeneron Pharmaceuticals Roche Samsung Bioepis Samsung BioLogics Sandoz Sanofi Schering-Plough Shanghai CP Buojian Pharmaceutical Sidmak Labs Sol-Gel Technologies Ltd Sun Pharma Sunovion Takeda Tanabe Tanja Todberg Taro Pharmaceuticals Teva Thesan Pharmaceuticals Inc Topica Pharmaceuticals UCB Valeant Vical Warner Chilcott Watson Pharmaceuticals Xenon Pharmaceuticals Ziarco Group Limited Zydus

To see a report overview please e-mail Sara Peerun on

SOURCE Visiongain

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store